New data provide treatment insights into options for switching adult patients diagnosed with schizophrenia to uzedy® (risperidone) extended-release injectable suspension from perseris® (rbp-7000)

Tel aviv, israel and parsippany, n.j., sept. 21, 2024 (globe newswire) -- teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today presented data informing clinical strategies for switching patients to uzedy®, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, from a once-monthly subcutaneous injection of perseris ® (rbp-7000). the results were presented during the 37th annual european college of neuropsychopharmacology (ecnp) congress taking place between september 21-24, 2024, in milan, italy.
TEVA Ratings Summary
TEVA Quant Ranking